23 / 34
Aflibercept Is Effective Across Relevant Patient Subgroups
HR for OS (95% CI)
KRAS
WT
KRAS
MUT
RAS
WT
RAS
MUT
BRAF
MUT
BRAF
WT/
RAS
WT
Left-sided primary tumor*
Right-sided primary tumor*
0.74 (0.60-0.99)
0.90 (0.65-1.24)
0.70 (0.50-0.97)
0.93 (0.7-1.23)
0.42 (0.16-1.09)
0.84 (0.67-1.05)
0.86 (0.64-1.15)
0.85 (0.53-1.35)
0.5
0.75
1.25
1.0
Angiogenesis Biomarkers remain elusive…
Tejpar, World GI 2017